Product FAQ

Home / Vika QA pages

Xpert® Carba-R

Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 50 minutes

Per visualizzare i prezzi, accedi o crea un account MyCepheid

Dimensioni della confezione di prova

10 Test

GXCARBARP-CE-10

Q.tà

Prezzo unitario

Subtotale

USD

$0.00

10 Test

GXCARBAR-CE-10

Q.tà

Prezzo unitario

Subtotale

USD

$0.00

Dispositivi di prelievo

Collection Device (Pack of 50)

900-0370

Q.tà

Prezzo unitario

Subtotale

USD

$0.00

Single Use Disposable Swab (Pack of 120)

SDPS-120

Q.tà

Prezzo unitario

Subtotale

USD

$0.00

Totale

$0.00

The Need

The emergence and global spread of carbapenemase producing Enterobacterales (CPE) is of great concern to health services worldwide¹
Carbapenem resistance results in increased mortality in hospitalized patients and is associated with higher total hospital costs²
CPE are multi-drug resistant organisms that can cause serious infections and require interventions in healthcare settings to prevent spread³
ECDC and CDC recommend comprehensive infection control measures for patients who are colonized or infected with carbapenemase-producing organisms^3,4

1 Bonomo RA, Burd EM, Conly J, Limbago BM, Poirel L, Segre JA, Westblade LF. Carbapenemase-Producing Organisms: A Global Scourge. Clin Infect Dis. 2018 Apr 3;66(8):1290-1297. doi: 10.1093/cid/cix893. PMID: 29165604; PMCID: PMC5884739.
2 Judd WR, et al. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. American Journal of Infection Control. June 2016. http://www.sciencedirect.com/science/article/pii/S0196655316303431
3 CDC Healthcare Facilities: Information about CRE https://www.cdc.gov/hai/organisms/cre/cre-facilities.html
4 ECDC RAPID RISK ASSESSMENT. Carbapenem-resistant Enterobacteriaceae–second update. 26 Sept. 2019. Accessed June 2020 https://www.ecdc.europa.eu/sites/portal/files/documents/carbapenem-resistant-enterobacteriaceae-risk-assessment-rev-2.pdf

The Solution

Detection and differentiation of patients with the Xpert Carba-R test can quickly alert clinicians and infection preventionists to the presence of gene sequences associated with carbapenem non-susceptibility
Rapid detection and differentiation of the KPC, NDM, VIM, IMP, and OXA-48 gene sequences from pure colonies helps clinicians optimize patient management and direct therapeutic strategy
Rectal and perirectal swabs assist with infection control measures
On-demand identification of the most prevalent carbapenemase gene families enables healthcare systems to prevent onward transmission throughout the patient pathway and facilitates more efficient bed management for improved hospital flow⁵

The Impact

Reduced turnaround time enables rapid infection control measure to reduce transmission^6,7
Significant reduction the number of bed-days lost due to CPE compared to culture⁵
Significant decrease in CPE colonization and infection rates with fast PCR results⁸

5 Corless C. et al. Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting. IPIP. 2020 May;3(2):100011.
6 Jin S, Lee JY, Park JY, Jeon MJ. Xpert Carba-R assay for detection of carbapenemase-producing organisms in patients admitted to emergency rooms. Medicine (Baltimore). 2020 Dec 11;99(50):e23410.
7 Ambretti S et al. Total integration of cultural and molecular testing for CPE screening with liquid based microbiology (LBM). Poster presented at ECCMID. 2018 21-24 April. Madrid, Spain.
8 Zhou M, Kudinha T, Du B, Peng J, Ma X, Yang Y, Zhang G, Zhang J, Yang Q, Xu YC. Active Surveillance of Carbapenemase-Producing Organisms (CPO) Colonization With Xpert Carba-R Assay Plus Positive Patient Isolation Proves to Be Effective in CPO Containment. Front Cell Infect Microbiol. 2019 May 14;9:162. doi: 10.3389/fcimb.2019.00162. PMID: 31157176; PMCID: PMC6528581.